Just been looking at some solid dividend plays heading into the rest of 2026, and honestly, two healthcare stocks keep standing out to me: Johnson & Johnson and Zoetis. These aren't flashy picks, but they're exactly what income-focused investors should have on their radar.

Let me start with J&J. The thing about this company is that it's boring in the best way possible. Yeah, it's not going to make headlines like some hot growth stock, but that consistency is actually the whole point. Their pharmaceutical business is massive, they've got a deep medical device portfolio, and they're pulling in revenues that just keep climbing. Even with patent cliffs and drug pricing pressure from the government, they're projecting sales growth this year and should cross $100 billion in annual revenue for the first time. That's huge.

What really matters here is the balance sheet. Johnson & Johnson's credit rating is literally better than the U.S. government's. They're also constantly innovating - they've got this robotic-assisted surgery system called Ottava coming down the pipeline that could be a major growth catalyst. And their pharma division has dozens of clinical trials running. It's this combination of innovation and financial strength that's kept them performing well for decades.

But here's the real kicker: J&J is a Dividend King. That means 50+ consecutive years of dividend increases. That's not luck - that's a business model that actually works. If you're looking for stocks to buy that can generate reliable income, this fits the bill perfectly.

Now, Zoetis took some hits last year. Their osteoarthritis treatments for pets - Librela for dogs and Solensia for cats - ran into safety concerns that spooked investors. But they've already moved forward with newer products: Lenivia and Portela. These are actually better than what came before because they last longer, so they'd probably gain market share anyway. The company's track record of launching better products consistently is solid.

What's interesting about Zoetis is that they're riding a real demographic trend. Younger people increasingly prefer owning pets to having kids, which means sustained demand for animal healthcare. They've already got Apoquel, their allergic itch treatment for dogs, which despite being over a decade old still has huge untreated market potential globally. Over the past ten years, their dividend is up 458%. That's the kind of growth income investors dream about.

Both of these healthcare stocks to buy have the resilience to keep paying dividends even when markets get rough. They're not going to suspend or cut payouts at the first sign of trouble. That's what separates them from most dividend stocks out there. If you're building a portfolio focused on reliable income, these two deserve serious consideration for 2026.